PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1804.99%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -6.27%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
-2.82%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-210.31%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-18.66%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
83.67%
Working capital of 83.67% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
213.16%
AR growth of 213.16% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
55.06%
Inventory growth of 55.06% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
-105.54%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
3.34%
Growth of 3.34% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
386.89%
Growth of 386.89% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
90.83%
CFO growth of 90.83% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
37.83%
CapEx growth of 37.83% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
319.83%
Acquisition growth of 319.83% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
103.42%
Purchases growth of 103.42% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
-116.21%
We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.
3144.44%
Growth of 3144.44% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
105.19%
Investing flow of 105.19% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
-24.59%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-103.42%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.